Daniel R. Passeri Purchases 30,000 Shares of Cue Biopharma, Inc. Stock
CUE Stock | USD 1.01 0.01 0.98% |
About 54% of Cue Biopharma's investor base is interested to short. The analysis of the overall investor sentiment regarding Cue Biopharma suggests that many traders are impartial. The current market sentiment, together with Cue Biopharma's historical and current headlines, can help investors time the market. In addition, many technical investors use Cue Biopharma stock news signals to limit their universe of possible portfolio assets.
Cue |
Cue Biopharma, Inc. CEO Daniel R. Passeri purchased 30,000 shares of the firms stock in a transaction on Monday, December 16th. The stock was bought at an average price of 1.03 per share, for a total transaction of 30,900.00. Following the acquisition, the chief executive officer now owns 164,578 shares
Read at thelincolnianonline.com
Cue Biopharma Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Cue Biopharma can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Cue Biopharma Fundamental Analysis
We analyze Cue Biopharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cue Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cue Biopharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Gross Profit
Gross Profit Comparative Analysis
Cue Biopharma is currently under evaluation in gross profit category among its peers. Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.
Cue Biopharma Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Cue Biopharma stock to make a market-neutral strategy. Peer analysis of Cue Biopharma could also be used in its relative valuation, which is a method of valuing Cue Biopharma by comparing valuation metrics with similar companies.
Peers
Cue Biopharma Related Equities
CGTX | Cognition Therapeutics | 8.62 | ||||
ANIX | Anixa Biosciences | 6.32 | ||||
INAB | In8bio | 4.17 | ||||
DRMA | Dermata Therapeutics | 2.86 | ||||
DAWN | Day One | 2.65 | ||||
FENC | Fennec Pharmaceuticals | 2.57 | ||||
COYA | Coya Therapeutics, | 1.55 | ||||
TCRX | Tscan Therapeutics | 1.37 | ||||
INMB | INmune Bio | 0.45 | ||||
LTRN | Lantern Pharma | 1.87 | ||||
TERN | Terns Pharmaceuticals | 3.14 | ||||
XFOR | X4 Pharmaceuticals | 4.69 | ||||
HOOK | Hookipa Pharma | 5.61 | ||||
PYPD | PolyPid | 8.00 |
Complementary Tools for Cue Stock analysis
When running Cue Biopharma's price analysis, check to measure Cue Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cue Biopharma is operating at the current time. Most of Cue Biopharma's value examination focuses on studying past and present price action to predict the probability of Cue Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cue Biopharma's price. Additionally, you may evaluate how the addition of Cue Biopharma to your portfolios can decrease your overall portfolio volatility.
Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
Bonds Directory Find actively traded corporate debentures issued by US companies | |
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
Stocks Directory Find actively traded stocks across global markets | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance |